Effect of rimonabant and metformin on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 in obese women with polycystic ovary syndrome.
Sathyapalan
Thozhukat
T
Cho
LiWei
L
Kilpatrick
Eric S
ES
Le Roux
Carel W
CW
Coady
Anne-Marie
AM
Atkin
Stephen L
SL
D004359:Drug Therapy, Combination; D005260:Female; D005749:Gastric Inhibitory Polypeptide / Q000097:blood*; D052216:Glucagon-Like Peptide 1 / Q000097:blood*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D008687:Metformin / Q000494:pharmacology / Q000627:therapeutic use*; D009765:Obesity / Q000150:complications / Q000188:drug therapy; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use*; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D011720:Pyrazoles / Q000494:pharmacology / Q000627:therapeutic use*; D000077285:Rimonabant
D007004:Hypoglycemic Agents; D010880:Piperidines; D011720:Pyrazoles; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1; D008687:Metformin; D000077285:Rimonabant